Reversal of liver cirrhosis: A desirable clinical outcome and its pathogenic background

Journal of Pediatric Gastroenterology and Nutrition

Volumn 44, Issue 4, 2007, Pages 401-406

  Bortolotti, Flavia ^a,c   Guido, Maria ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c Clinica Medica V   (Italy)

Author keywords

Cirrhosis, reversible; Fibrogenesis; Fibrolysis; Hepatitis

Indexed keywords

ANTIFIBROTIC AGENT; AZATHIOPRINE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; LAMIVUDINE; METHOTREXATE; PEGINTERFERON; RIBAVIRIN; STEROID;

BIOACCUMULATION; BONE MARROW TRANSPLANTATION; CELL DEATH; COMBINATION CHEMOTHERAPY; DELTA AGENT HEPATITIS; DISEASE SEVERITY; EXTRACELLULAR MATRIX; FIBROGENESIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LIVER BIOPSY; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; MONOTHERAPY; MYOFIBROBLAST; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STELLATE CELL; THALASSEMIA; VIREMIA;

ANTI-INFLAMMATORY AGENTS; ANTIVIRAL AGENTS; BIOPSY; HEPATITIS, VIRAL, HUMAN; HUMANS; INTERFERON ALFA-2B; LIVER; LIVER CIRRHOSIS; LIVER DISEASES; RIBAVIRIN;

EID: 34147150694     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e318032069a     Document Type: Review

References (62)

1. Anthony PP, Ishak KG, Nayak NC, et al. The morphology of cirrhosis: definition, nomenclature and classification. Bull WHO 1977;55:521-40.
2. D'Amico G, Garcia Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-31.
3. Benvegnù L, Gios M, Boccato S, et al. Natural history of compensated viral cirrhosis: a prospective study of the incidence and hierarchy of major complications. Gut 2004;53:744-9.
4. Desmet V, Roskams T. Cirrhosis reversal: a duel between dogma and myth. J Hepatol 2004;40:860-7.
5. Beyon RC, Iredale JP. Is liver fibrosis reversible? Gut 2000;46:443-6.
6. Bonis PAL, Friedman SL, Kaplan MM. Is liver fibrosis reversible? N Engl J Med 2001;344:452-4.
7. Arthur MJP. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 2002;122:1525-8.
8. Iredale JP. Cirrhosis: new research provides basis for rationale and targeted treatments. BMJ 2002;327:143-7.
9. Pol S, Carnot F, Nalpas B, et al. Reversibility of hepatitis C virus related cirrhosis. Hum Pathol 2004;35:108-12.
10. Fallowfield JA, Iredale JP. Reversal of liver fibrosis and cirrhosis: an emerging reality. Scott Med J 2004;49:3-6.
11. Friedman SL, Bansal MB. Reversal of hepatic fibrosis: fact or fantasy. Hepatology 2006;43:S82-8.
12. Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997;127:981-5.
13. Wanless IR. Use of corticosteroid therapy in autoimmune hepatitis resulting in the resolution of cirrhosis. J Clin Gastroenterol 2001;32:371-2.
14. Kaplan MM, DeLellis RA, Wolfe HJ. Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment. Ann Intern Med 1997;26:682-8.
15. Hammel P, Couvelard A, O'Toole D, et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 2001;344:418-23.
16. Cotler SJ, Jakate S, Jenken DM. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J Clin Gastroenterol 2001;32:428-30.
17. Muretto P, Angelucci E, Lucarelli G. Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. Ann Intern Med 2002;136:667-72.
18. Kweon YO, Goodman ZD, Dienstag JL, et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 2001;35:749-55.
19. Lau DT, Kleiner DE, Park Y, et al. Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology 1999;17:1229-33.
20. Farci P, Roskams T, Chessa L, et al. Long-term benefit of interferon alfa therapy of chronic hepatitis D: regression of hepatic advanced fibrosis. Gastroenterology 2004;126:1740-7.
21. Poynard T, McHutchison J, Davies GL, et al. Impact of interferon alfa-2b on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000;32:1131-7.
22. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13.
23. Pol S, Carnot F, Nalpas B, et al. Reversibility of hepatitis C virus related cirrhosis. Hum Pathol 2004;35:108-12.
24. Friedman SL, Roll FJ, Boyles J, et al. Hepatic lypocites: the principal collagen producing cells of normal rat liver. Proc Natl Acad Sci USA 1985;82:8681-5.
25. Tsukada S, Parsons CJ, Rippe RA. Mechanisms of liver fibrosis. Clin Chim Acta 2006;364:33-60.
26. Friedman SL. Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 2004;2:98-105.
27. Alcolado R, Arthur MJP, Iredale JP. Pathogenesis of liver fibrosis. Clin Sci 1997;92:103-12.
28. Wanless IR. Pathogenesis of cirrhosis. J Gastroenterol Hepatol 2004;19:S369-71.
29. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-18.
30. Pinzani M, Rambout K. Liver fibrosis from the bench to clinical targets. Dig Liver Dis 2004;36:231-42.
31. Wanless IR, Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis 2004;24:99-106.
32. Kutami R, Girgrah N, Wanless IR, et al. The Laennec grading system for assessment of hepatic fibrosis: validation by correlation with wedged hepatic vein pressure and clinical features. Hepatology 2000;32:407A.
33. Nagula S, Jain D, Groszman RJ, et al. Histological-hemodynamic correlation in cirrhosis: a histological classification of the severity of cirrhosis. J Hepatol 2006;44:111-7.
34. Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis: morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000;124:1599-607.
35. Desmet VJ, Sciot R, Van Eyken P. Differential diagnosis and prognosis of cirrhosis: role of liver biopsy. Acta Gastroenterol Belg 1990;53:198-208.
36. Friedman SL. The cellular basis of hepatic fibrosis: mechanisms and treatment strategies. N Engl J Med 1993;328:1823-35.
37. Geerts A. History, heterogeneity, developmental biology, and function of quiescent hepatic stellate cells. Semin Liver Dis 2002;21:311-35.
38. Iredale JP. Hepatic stellate cell behaviour during resolution of liver injury. Semin Liver Dis 2001;21:227-36.
39. Desmoulière A, Darby I, Costa AM, et al. Extracellular matrix deposition lysil-oxidase expression, and myofibroblastic differentiation during the initial stages of cholestatic fibrosis in the rat. Lab Invest 1997;76:765-78.
40. Bhunchet E, Wake K. Role of mesenchymal cell populations in porcine serum-induced rat liver fibrosis. Hepatology 1992;16:1452-73.
41. Ramadori G, Saile B. Portal tract fibrogenesis in the liver. Lab Invest 2004;84:153-9.
42. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730-9.
43. Aimes RT, Quigley JP. Matrix metalloprotease-2 is an interstitial collagenase inhibitor free enzyme that catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem 1995;270:5872-6.
44. Arthur MJP, Iredale JP, Mann DA. Tissue inhibitors of metalloproteinases: role in liver fibrosis and alcoholic liver disease. Alcohol Clin Express 1999;23:940-3.
45. Elsharkawy AM, Oakley F, Mann DA. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 2005;10:927-39.
46. Kavada N. Human hepatic stellate cells are resistant to apoptosis: implications for human fibrogenic liver disease. Gut 2006;55:1073-4.
47. Issa R, Zhou X, Constandinou CM, et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004;126:1785-808.
48. Powell LW, Ker JF. Reversal of "cirrhosis" in idiopathic hemochromatosis following long-term intensive venesection therapy. Australas Ann Med 1970;2:54-7.
49. Falkmer S, Samuelson G, Sjolin S. Penicillamine-induced normalization of clinical signs and liver morphology and histochemistry in a case of Wilson's disease. Pediatrics 1970;45:260-8.
50. Bortolotti F, Guido M, Cadrobbi P, et al. Spontaneous regression of hepatitis B virus associated liver cirrhosis developed in childhood. Dig Liver Dis 2004;37:964-7.
51. Bortolotti F, Guido M, Bartolacci S, et al. Chronic hepatitis B in children following e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology 2006;43:556-62.
52. Guido M, Rugge M. Liver fibrosis: natural history may be affected by the biopsy sample. Gut 2004;53:451-5.
53. Guido M, Rugge M. Liver biopsy sampling in chronic viral hepatitis. Semin Liver Dis 2004;24:89-97.
54. Regev A, Berho M, Lennox JJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614-8.
55. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1356-8.
56. Colloredo G, Sonzogni A, Leandro G, et al. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003;39:239-44.
57. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
58. Poynard T, Bedossa P, Opolon P, et al. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-32.
59. Ishak KG, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
60. Sebastiani G, Alberti A. Noninvasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006;21:3682-94.
61. Prosser CC, Yen RD, Wu J. Molecular therapy for hepatic injury and fibrosis: where are we? World J Gastroenterol 2006;12:509-15.
62. Albanis E, Friedman SL. Antifibrotic agents for liver disease. Am J Transplant 2006;6:12-9.